CareDx, Inc. $CDNA is Gagnon Securities LLC’s 5th Largest Position

Gagnon Securities LLC boosted its position in CareDx, Inc. (NASDAQ:CDNA) by 11.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,729,425 shares of the company’s stock after buying an additional 180,513 shares during the period. CareDx makes up approximately 5.0% of Gagnon Securities LLC’s portfolio, making the stock its 5th largest holding. Gagnon Securities LLC’s holdings in CareDx were worth $25,146,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of CDNA. Allworth Financial LP acquired a new stake in shares of CareDx in the 2nd quarter worth $40,000. State of Alaska Department of Revenue purchased a new position in CareDx during the third quarter worth about $43,000. Tower Research Capital LLC TRC lifted its position in CareDx by 120.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company’s stock valued at $149,000 after purchasing an additional 4,160 shares during the period. RiverPark Advisors LLC acquired a new stake in CareDx in the second quarter valued at about $149,000. Finally, AlphaQuest LLC boosted its holdings in CareDx by 40.0% in the 2nd quarter. AlphaQuest LLC now owns 9,576 shares of the company’s stock valued at $187,000 after purchasing an additional 2,736 shares in the last quarter.

Insider Buying and Selling at CareDx

In other news, CEO John Walter Hanna, Jr. sold 19,280 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $21.16, for a total transaction of $407,964.80. Following the completion of the transaction, the chief executive officer directly owned 597,405 shares of the company’s stock, valued at $12,641,089.80. This trade represents a 3.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 29,636 shares of company stock worth $625,949. Company insiders own 4.40% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on CDNA shares. Weiss Ratings reissued a “hold (c-)” rating on shares of CareDx in a research note on Monday, December 29th. Craig Hallum cut CareDx from a “buy” rating to a “hold” rating and set a $26.00 price objective for the company. in a research report on Tuesday, January 6th. Wall Street Zen upgraded shares of CareDx from a “hold” rating to a “buy” rating in a research report on Sunday, December 21st. BTIG Research upped their price target on shares of CareDx from $22.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Finally, Zacks Research upgraded shares of CareDx from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 18th. Three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, CareDx has a consensus rating of “Hold” and a consensus target price of $26.67.

CareDx Stock Up 1.7%

Shares of CDNA stock opened at $20.80 on Friday. The stock has a market cap of $1.07 billion, a P/E ratio of 17.48 and a beta of 2.49. CareDx, Inc. has a fifty-two week low of $10.96 and a fifty-two week high of $25.55. The business has a fifty day simple moving average of $19.32 and a 200-day simple moving average of $15.94.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.15. The firm had revenue of $100.06 million for the quarter, compared to analysts’ expectations of $95.25 million. CareDx had a net margin of 19.65% and a return on equity of 20.15%. The firm’s revenue was up 20.7% on a year-over-year basis. During the same period in the prior year, the company earned ($0.14) EPS. On average, sell-side analysts anticipate that CareDx, Inc. will post -0.9 earnings per share for the current year.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.